In vivo cardiac electrophysiologic and antiarrhythmic effects of an isoquinoline IKur blocker, ISQ-1, in rat, dog, and nonhuman primate

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 4, 2007, Pages 236-245

  Regan, Christopher P ^a   Stump, Gary L ^a   Wallace, Audrey A ^a   Anderson, Kenneth D ^a   McIntyre, Charles J ^a   Liverton, Nigel J ^a   Lynch Jr , Joseph J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiarrhythmic; Atrial arrhythmia; Atrial fibrillation

Indexed keywords

IBUTILIDE; ISOQUINOLINE 1; ISOQUINOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CERCOPITHECIDAE; CONTINUOUS INFUSION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG DOSE SEQUENCE; DRUG EFFECT; FEMALE; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ATRIAL FLUTTER; ATRIAL FUNCTION; BLOOD PRESSURE; CERCOPITHECUS AETHIOPS; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGIC TECHNIQUES, CARDIAC; FEMALE; HEART CONDUCTION SYSTEM; HEART RATE; INFUSIONS, INTRAVENOUS; ISOQUINOLINES; MALE; POTASSIUM CHANNEL BLOCKERS; PRIMATES; RATS; RATS, SPRAGUE-DAWLEY; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; TIME FACTORS;

EID: 34247282162     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180325b2a     Document Type: Article

References (40)

1. Valderrama AL, Dunbar SB, Mensah GA. Atrial fiibrillation. Public health implications. Am J Prev Med. 2005;29:75-80.
2. Waldo AL. A perspective on antiarrhythmic drug therapy to treat atrial fibrillation: There remains an unmet medical need. Am Heart J. 2006;151:771-778.
3. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, et al. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation. A systematic review of randomized controlled trials. Arch Intern Med. 2006;166:719-728.
4. Vos MA. Atrial-specific drugs: The way to treat atrial fibrillation? J Cardiovasc Electrophysiol. 2004;15:1451-1452.
5. Hesketh JC, Herrera D, Zicha S, et al. Novel targets for cardiac antiarrhythmic drug development. Curr Pharmaceut Design. 2005;11:1959-1974.
6. Kur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Therap. 2005;315:1362-1367.
7. Kur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J Pharmacol Exp Therap. 2006;316:727-732.
8. + channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Therap. 2006;317:1054-1063.
9. Trotter BW, Nanda KK, Kett NR, et al. Design and synthesis of 3-cyanoisoquinolines as orally bioavailable Kv1.5 antagonists for the treatment of atrial fibrillation. J Med Chem. 2006;49:6954-6957.
10. + current in guinea pig ventricular cells. J Pharmacol Exp Therap. 1992;262:99-108.
11. Kr) in AT-1 cells. Circulation. 1995;91:1799-1806.
12. Regan CP, Cresswell HK, Zhang R, et al. Novel method to assess cardiac electrophysiology in the rat: Characterization of standard ion channel blockers. J Cardiovasc Pharmacol. 2005;46:68-75.
13. Ks blockers. J Cardiovasc Pharmacol. 2003;42:105-112.
14. Frame LH, Page RL, Hoffman BF. Atrial reentry around an anatomic barrier with a partially refractory excitable gap. Circ Res. 1986;58:495-511.
15. + current similar to Kv1.5 cloned channel currents. Circ Res. 1993;73:1061-1076.
16. Amos GJ, Wettwer E, Metzger F, et al. Differences between outward currents of human atrial and subepicardial ventricular myocytes. J Physiol. 1996;491:31-50.
17. Blass BE, Coburn K, Lee W, et al. Synthesis and evaluation of (2-phenyl-2H-1,2,3-triazol-4-yl)(phenyl)methanones as Kv1.5 channel blockers for the treatment of atrial fibrillation. Bioorgan Med Chem Letters. 2006;16:4629-4632.
18. + channel Kv1.5 current. Life Sci. 2001;68:2017-2024.
19. Seki A, Hagiwara N, Kasanuki H. Effects of NIP-141 on K currents in human atrial myocytes. J Cardiovasc Pharmacol. 2002;39:29-38.
20. Nagasawa H, Fujiki A, Fujikura N, et al. Effects of a novel Class III antiarrhythmic agent, NIP-142, on canine atrial fibrillation and flutter. Circ J. 2002;66:185-191.
21. Matsuda T, Takeda K, Ito M, et al. Atria selective prolongation by NIP-142, an antiarrhythmic agent, of refractory period and action potential duration in guinea pig myocardium. J Pharmacol Sci. 2005;98:33-40.
22. Gogelein H, Brendel J, Steinmeyer K, et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn-Schmiedeberg's Arch Pharmacol. 2004;370:183-192.
23. KAch Class IC drugs and beta blockers in pigs. Med Sci Monit. 2004;10:BR221-BR228.
24. Blaauw Y, Gogelein H, Tieleman RG, et al. "Early" Class III drugs for the treatment of atrial fibrillation. Efficacy and atrial selectivity of AVE0118 in remodeled atria of the goat. Circulation. 2004;110:1717-1724.
25. Kur in controlling action potential shape and contractility in the human atrium. Influence of chronic atrial fibrillation. Circulation. 2004;110:2299-2306.
26. Fedida D, Orth PMR, Chen JYC, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1-12.
27. Nattel S, DeBlasio E, Beach GN, et al. RSD1235: a novel antiarrhythmic agent with a unique electrophysiological profile that terminates AF in dogs. Eur Heart J. 2001;22:448.
28. Beatch GN, Shinagawa K, Johnson B, et al. RSD1235 selectively prolongs atrial refractoriness and terminates AF in dogs with electrically remodeled atria. PACE. 2002;25:698.
29. Beatch GN, Helmes M, Blaauw Y, et al. Acute reversal of electrical remodeling and cardioversion of persistent AF by a novel atria-selective antiarrhythmic drug, RSD1235, in the goat. Circulation. 2004;110:III-163.
30. Roy D, Rowe BH, Stiell IG, et al. A randomized controlled trial of RSD1235, a novel antiarrhythmic agent, in the treatment of recent onset atrial fibrillation. J Am Coll Cardiol. 2004;44:2355-2361.
31. Dorian P, Mangat I, Korley V, et al. The investigational antiarrhythmic agent RSD1235 is atrial selective in humans. Circulation. 2005;112:II-494.
32. + currents in isolated adult rat ventricular myocytes. J Gen Physiol. 1991;97:973-1011.
33. + current in isolated rat atrial myocytes. Am J Physiol. 1991;260:H1236-H1247.
34. Roberds SL, Tamkun MM. Cloning and tissue-specific expression of five voltage-gated potassium channel cDNAs expressed in rat heart. Proc Natl Acad Sci. 1991;88:1798-1802.
35. Dixon JE, McKinnon D. Quantitative analysis of potassium channel mRNA expression in atrial and ventricular muscle of rats. Circ Res. 1994;75:252-260.
36. + current in canine atrial myocytes. Circ Res. 2003;93:744-751.
37. + channel blocker AVE0118. Circulation. 2004;110:III-318.
38. Frame LH, Page RL, Boyden PA, et al. Circus movement in the canine atrium around the tricuspid ring during experimental atrial flutter and during reentry in vitro. Circulation. 1987;76:1155-1175.
39. Boyden PA, Frame LH, Hoffman BF. Activation mapping of reentry around an anatonic barrier in the canine atrium. Observations during entrainment and termination. Circulation. 1989;79:406-416.
40. Roithinger FX, Lesh MD. What is the relationship of atrial flutter and fibrillation? PACE. 1999;22:643-654.